NGS-based Thyroscan Genomic Classifier in the Diagnosis of Thyroid Nodules
Prospective, Blinded, Multi-center Clincal Study of NGS-based Thyroscan Genomic Classifier in the Diagnosis of Thyroid Nodules
研究概览
详细说明
The prevalence of thyroid nodules by high-resolution ultrasound can be as high as 20%, though most of them are benign lesions, only about 5%-15% are malignant lesions. Based on 1.4 billion population in China, there are approximately 280 million thyroid nodule carriers, of which approximately 14-42 million are potential patients with thyroid cancer. Now thyroid cancer is the fastest growing cancer and the 4th most common cancer in women in China. Therefore, the key point in the evaluation of thyroid nodules is the differential diagnosis of benign and malignant nodules. At present, the commonly used imaging and cytological diagnostic techniques for thyroid nodules include ultrasound and ultrasound-guided fine needle aspiration biopsy (FNAB), as well as emerging molecular diagnostic techniques.
The purpose of this study is to evaluate the accuracy of Thyroscan in the diagnosis of benign and malignant thyroid nodules with suspecious ultrasound features. For patients who have signed an informed consent, the subjects undergo fine needle aspiration of thyroid nodules classified as C-TIRADS catagories 3 or 4 under the guidance of ultrasound or palpation before receiving surgical treatment. One needle is used to prepare cytological smear, and one needle is preserved and sent to Thyroscan detection.
研究类型
注册 (实际的)
联系人和位置
学习地点
-
-
-
Hangzhou、中国、310000
- Zhejiang Provincial People's Hospital
-
Shanghai、中国、200000
- Shanghai Jiaotong University School of Medicine
-
Tianjin、中国、300000
- Tianjin Medical University Center Hospital
-
-
Jiangsu
-
Changzhou、Jiangsu、中国、213000
- The First Peple's Hospital of Changzhou
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
取样方法
研究人群
描述
Inclusion Criteria:
- Patients sign the informed consent form for participating in the reasearch study.
- Patient's age is 18 years or older.
- Ultrasound showed at least one thyroid nodule, and it was classified as C-TIRADS Category 3/4.
- The surgeon has confirmed surgical indication and the subject is willing to undergo the planned surgical intervention at the participating medical institution; or cytology results are benign, and the nodule(s) have remained clinically stable-defined as absence of new high-risk ultrasound features and no significant change in size on serial imaging.
- Surgical indications include but are not limited to one of the following conditions: 1) Thyroid nodules are compressed or affect aesthetics; 2) The patient's subjective wishes require surgical removal of the nodules; 3) FNA samples with indeterminate cytology are classified as Bethesda III and IV, requiring diagnostic surgery; 4) After the investigator's assessment, there are other surgical indications.
- Preoperative FNAB to obtain sufficient cells.
Exclusion Criteria:
- The subject has a history of thyroid tumor.
- The subject is not suitable for fine-needle aspiration biopsy and surgical treatment due to other conditions such as comorbid diseases.
- Subjects who intend to receive the radiofrequency ablation therapy.
- Other conditions determined by the researcher that do not meet the criteria of enrollment.
学习计划
研究是如何设计的？
设计细节
队列和干预
团体/队列 |
干预/治疗 |
|---|---|
|
Ultrasound findings of thyroid nodules classified as type 3 and 4 of C-TIRADS
|
To evaluate the accuracy of Thyroscan in the differential diagnosis of benign and malignant thyroid nudules with abnormal ultrasound features.
|
研究衡量的是什么？
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
To evaluation of Thyroscan's performance in diagnosing thyroid nodules
大体时间：At the time of postsurgical pathology report, or upon completion of the 12-month follow-up for non-surgical participants.
|
To explore the sensitivity, specificity, positive predictive value, negative predictive value, consistency and Kappa value of Thyroscan in the diagnosis of thyroid nodules with ultrasound features classified as C-TIRADS category 3/4.
|
At the time of postsurgical pathology report, or upon completion of the 12-month follow-up for non-surgical participants.
|
次要结果测量
结果测量 |
大体时间 |
|---|---|
|
To compared with cytopathology and Thyroscan in diagnosing thyroid nodules.
大体时间：At the time of postsurgical pathology report, or upon completion of the 12-month follow-up for non-surgical participants.
|
At the time of postsurgical pathology report, or upon completion of the 12-month follow-up for non-surgical participants.
|
其他结果措施
结果测量 |
大体时间 |
|---|---|
|
To reveals the correlation between molecular landscape and clinical-pathological characteristics of thyroid nodules.
大体时间：At the time of postsurgical pathology report, or upon completion of the 12-month follow-up for non-surgical participants.
|
At the time of postsurgical pathology report, or upon completion of the 12-month follow-up for non-surgical participants.
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索，没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求，请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改，我们的网站上也会自动更新.